Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Looks Good-ONCY SITC 2023 Poster in metastatic breast cancer

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 05, 2023 9:46am

196 Views

Post# 35718216

RE:Looks Good-ONCY SITC 2023 Poster in metastatic breast cancer

This work further adds to the increasing evidence that pelareorep remodels an otherwise immunosuppressive TME and primes the immune system in preparation for the administration of the checkpoint inhibitor atezolizumab.

<< Previous

Bullboard Posts

Next >>

This junior mining stock offers billions in market exposure